Antimicrobial resistance (AMR)

Antimicrobial resistance (AMR) threatens to undermine a century of medical progress, with drug-resistant infections already claiming over 1.2 million lives annually. Without action, AMR could cause 10 million deaths per year by 2050 and trigger economic losses comparable to the 2008 financial crisis.

LSE Health is at the forefront of AMR policy research, recently partnering with WHO Europe to develop the world's first AMR Accountability Index. Our research examines the market failures that limit antibiotic development, evaluates policy interventions to promote appropriate antimicrobial use, and analyses governance mechanisms for coordinating global AMR responses. We work to identify sustainable solutions that balance access to life-saving antibiotics with the imperative to preserve their effectiveness for future generations.